Biocytogen antibodies meet a new class of payload
Biocytogen has proprietary antibody platforms and a broad oncology binder portfolio. GenLumina adds a differentiated intracellular payload whose cytotoxic activity is controlled by local light activation.
Target selection, intracellular delivery and local activation
The antibody determines which tumour cells are reached and internalized. GenLumina adds an independent spatial switch intended to control where the intracellular payload becomes active.
Binder selection
Biocytogen identifies a strongly validated oncology antibody with relevant internalization and developability data.
Conjugation
The selected binder is connected to GenLumina's ultra-small DNA–silver nanocluster payload through a suitable linker strategy.
Intracellular delivery
The conjugate is assessed for binding, uptake, intracellular localization, stability and retained payload function.
Spatial activation
Controlled local light activates the payload within the selected field to evaluate targeted tumour-cell killing and selectivity.
Biocytogen targeting biology determines where the payload goes. GenLumina light activation determines where it becomes active.
A preclinical platform ready for partner-specific validation
GenLumina can provide additional platform information for Biocytogen's internal R&D review under the parties' CDA. The precise package should match the selected binder and proposed experiment.
GenLumina foundation
- Light-activated intracellular oncology payload concept
- Targeted/conjugated in-vitro proof-of-concept
- Preclinical work in breast and colorectal cancer models
- Modular antibody- and peptide-targeting approach
- Controlled activation as a second selectivity layer
Binder-specific questions
- Target and indication relevance
- Internalization kinetics and intracellular trafficking
- Conjugation chemistry, loading and stability
- Binding retained after conjugation
- Light-controlled cytotoxicity and selectivity
A proprietary antibody engine seeking differentiated payload possibilities
Biocytogen brings fully human antibody discovery, proprietary oncology assets and preclinical capabilities. GenLumina brings a new payload mechanism that could extend those antibodies with an independent spatial activation layer.
Biocytogen's RenMice and RenSuper platforms provide a broad source of fully human monoclonal and bispecific antibodies for oncology development.
Biocytogen is actively exploring combinations of its antibodies with external conjugation and payload technologies to create next-generation ADC formats.
Biocytogen combines RenLite bispecific antibodies with Acepodia's external dual-payload conjugation technology. Their collaboration progressed from joint evaluation to an option-and-licence framework for selected programmes.
Validate the antibody–payload synergy with one focused programme
Biocytogen is preparing an oncology binder list. GenLumina can review the candidates for technical feasibility and oncology relevance, prioritizing strongly validated binders with favourable internalization.
Can a proprietary Biocytogen antibody deliver GenLumina's novel payload intracellularly and create a differentiated conjugate whose activity is spatially controlled by light?
Suggested work package
- Share and review a CDA-enabled shortlist with binder validation and internalization data
- Select one lead binder based on biology, oncology relevance and conjugation feasibility
- Define material requirements, linker strategy, controls and success criteria
- Assess conjugation, binding, stability, uptake and intracellular localization
- Evaluate light-controlled tumour-cell killing and decide whether to progress
Explore a feasibility study
A focused first programme could connect one strongly validated internalizing oncology binder with GenLumina's light-activatable payload and generate a clear technical decision point.